Comparison and Correlation of Neisseria meningitidis Serogroup B Immunologic Assay Results and Human Antibody Responses following Three Doses of the Norwegian Meningococcal Outer Membrane Vesicle Vaccine MenBvac

Loading...
Thumbnail Image
File version
Version of Record (VoR)
Author(s)
Findlow, Jamie
Taylor, Stephen
Aase, Audun
Horton, Rachel
Heyderman, Robert
Southern, Jo
Andrews, Nick J.
Barchha, Rita
Harrison, Ewan
Lowe, Ann
Boxer, Emma
Heaton, Charlotte
Balmer, Paul
Kaczmarski, Ed
Oster, Philipp
Gorringe, Andrew
Borrow, Ray
Miller, Elizabeth
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2006
Size
File type(s)
Location
License
Abstract

The prediction of efficacy of Neisseria meningitidis serogroup B (MenB) vaccines is currently hindered due to the lack of an appropriate correlate of protection. For outer membrane vesicle (OMV) vaccines, immunogenicity has primarily been determined by the serum bactericidal antibody (SBA) assay and OMV enzyme-linked immunosorbent assay (ELISA). However, the opsonophagocytic assay (OPA), surface labeling assay, whole blood assay (WBA), and salivary antibody ELISA have been developed although correlation with protection is presently undetermined. Therefore, the aim of the study was to investigate further the usefulness of, and relationships between, MenB immunologic assays. A phase II trial of the OMV vaccine, MenBvac, with proven efficacy was initiated to compare immunologic assays incorporating the vaccine and six heterologous strains. Correlations were achieved between the SBA assay, OMV ELISA, and OPA using human polymorphonuclear leukocytes and human complement but not between an OPA using HL60 phagocytic cells and baby rabbit complement. Correlations between the surface labeling assay, the SBA assay, and the OMV ELISA were promising, although target strain dependent. Correlations between the salivary antibody ELISA and other assays were poor. Correlations to the WBA were prevented since many samples had results greater than the range of the assay. The study confirmed the immunogenicity and benefit of a third dose of MenBvac against the homologous vaccine strain using a variety of immunologic assays. These results emphasize the need for standardized methodologies that would allow a more robust comparison of assays between laboratories and promote their further evaluation as correlates of protection against MenB disease.

Journal Title
Infection and Immunity
Conference Title
Book Title
Edition
Volume
74
Issue
8
Thesis Type
Degree Program
School
Publisher link
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2006 American Society for Microbiology. The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version.
Item Access Status
Note
Access the data
Related item(s)
Subject
Immunology not elsewhere classified
Biological Sciences
Agricultural and Veterinary Sciences
Medical and Health Sciences
Persistent link to this record
Citation
Collections